Predictors of response to chronic hepatitis C treatment

Annals of Hepatology

Volumn 9, Issue SUPPL. 1, 2010, Pages 54-60

  Coelho, Henrique Sergio Moraes ^a   Villela Nogueira, Cristiane Alves ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Genotype; Hepatitis C; Pegylated interferon ; Predictive factors; Sustained virological response.

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; IRON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; VITAMIN D; ANTIVIRUS AGENT; BIOLOGICAL MARKER;

ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIABETES MELLITUS; DNA POLYMORPHISM; DRUG EFFICACY; DRUG INDICATION; DRUG POTENTIATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; IRON OVERLOAD; LIVER FIBROSIS; MONOTHERAPY; NONHUMAN; ONSET AGE; PRESCRIPTION; PROGNOSIS; RACE DIFFERENCE; SEX DIFFERENCE; VIRUS DETECTION; VIRUS LOAD; VITAMIN BLOOD LEVEL; BLOOD; DRUG COMBINATION; ETHNIC GROUP; GENETIC POLYMORPHISM; GENETICS; HOSPITALIZATION; LIVER CIRRHOSIS; PATHOPHYSIOLOGY; PATIENT SELECTION; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; ETHNIC GROUPS; GAMMA-GLUTAMYLTRANSFERASE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; PATIENT SELECTION; POLYMORPHISM, GENETIC; RNA, VIRAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VIRAL LOAD;

EID: 79955938060     PISSN: 16652681     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1665-2681(19)31725-9     Document Type: Article

References (55)

1. Selzner N MI. How can we predict treatment response? In: Al Ave (Ed). Advances in the Therapy of Liver Disease. Barcelona: Ars Medica 1997: 271-277.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358(9286): 958-965.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FLJ, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347(13): 975-982.
4. Nelson DR, Davis GL, Jacobson I, Everson GT, Fried MW, Harrison SA, et al. Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol 2009; 7(4): 397-414.
5. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339(21):1485-492.
6. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352(9138): 1426-1432.
7. Davis GL, Esteban MR, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirinfor the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339(21):1493-1499.
8. Von WM, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129(2): 522-527.
9. Wright TL. Treatment of patients with hepatitis C and cirrhosis. Hepatology 2002; 36(5): S185-S194.
10. Iacobellis A, Siciliano M, Perri F, Annicchiarico BE, Leandro G, Caruso N, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis:A controlled study. J Hepatol 2007; 46(2): 206-212.
11. Bruno S, Crosignani A, Facciotto C, Rossi S, Roffi L, Redaelli A, et al. Sustained virologic response prevents the development of esophageal varices in compensated,child-pugh class a hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010;51(6): 1891-1893.
12. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42(2): 255-262.
13. Di Marco V, Almasio PL, Ferraro D, Calvaruso V, Alaimo G, Peralta S, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007; 47(4): 484-491.
14. Tekin F, Gunsar F, Karasu Z, Akarca U, Ersoz G. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Alimentary Pharmacology & Therapeutics 2008; 27(11): 1081-1085.
15. Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 2006; 55(4): 529-535.
16. Harrison SA. Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment. Clin Gastroenterol Hepatol 2008; 6(8): 864-876.
17. Harrison SA. Liver disease in patients with diabetes mellitus. J Clin Gastroenterol 2006; 40(1): 68-76.
18. Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology 2008; 134(2): 416-423.
19. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol 2005; 100(7): 1509-1155.
20. Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernández-Rodríguez CM, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005; 128(3): 636-641.
21. Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48(1): 28-34.
22. Elgouhari HM CK, López R, et al. Pioglitazone improves early virologic kinetic response to Peg IFN/RBV combination therapy in hepatitsC genotype 1 naïve patients. Hepatology 2008; 48: 383A.
23. Conjeevaran H BC, Mc Kenna et al. A randomized doubleblind placebo controlled study of PPAR gamma agonist pioglitazone given in combination with peginterferon and ribavirin in patients with genotype 1 chronic hepatitis C. Hepatology 2008; 48: 384A.
24. Romero GM, Fernández RCM, Andrade RJ, Diago M, Alonso S, Planas R, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008; 48(5): 721-727.
25. Dalgard O, Bjoro K, Hellum KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004; 40(6):1260-1265.
26. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44(1): 97-103.
27. Villela-Nogueira CA, Pérez RM, de Segadas Soares JA, Coelho HS. Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. J Clin Gastroenterol 2005; 39(8): 728-730.
28. Hernández A, Domper F, León A, Lorente R, López B, De la Santa E, et al. Viral kinetics during the first month of treatment in patients with genotype 1 chronic hepatitis C. Rev Esp Enferm Dig 2009; 101(10): 671-679.
29. De Segadas SJA, Villela NCA, Pérez RM, Nabuco LC, Brandao MCE, Coelho HS. Is the rapid virologic response a positivepredictive factor of sustained virologic response in allpretreatment status genotype 1 hepatitis c patients treated with peginterferon-alpha2b and ribavirin? J Clin Gastroenterol 2009; 43(4): 362-366.
30. Reddy KR, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30(3): 787-793.
31. Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Lybik M, et al. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepatitis 2001; 8(4): 264-269.
32. De María N, Colantoni A, Idilman R, Friedlander L, Harig J, Van Thiel DH. Impaired response to high-dose interferon treatment in African-Americans with chronic hepatitis C. Hepato-Gastroenterology 2002; 49(45): 788-792.
33. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350(22): 2265-2271.
34. Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S. Equally poor outcomes to pegylated interferon-basedtherapy in African Americans and Hispanics with chronichepatitis C infection. J Clin Gastroenterol 2010; 44(2):140-145.
35. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. New EnglJ Med 2009; 361(6): 580-593.
36. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461(7262): 399-401.
37. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461(7265): 798-801.
38. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nature Genetics 2009; 41(10): 1100-1104.
39. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide editorassociation of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nature Genetics 2009; 41(10): 1105-1109.
40. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated Association between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin. Gastroenterology 2010; 138(7): 2307-2314.
41. Anand BS, Currie S, Dieperink E, Bini EJ, Shen H, Ho SB, et al. Alcohol use and treatment of hepatitis C virus: resultsof a national multicenter study. Gastroenterology 2006;130(6): 1607-1616.
42. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronichepatitis C. Gastroenterology 1995; 108(4): 1104-1109.
43. Fargion S, Fracanzani AL, Sampietro M, Molteni V, Boldorini R, Mattioli M, et al. Liver iron influences the response tointerferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol1997; 9(5): 497-503.
44. Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden D, et al. Hepatic iron overload does not prevent asustained virological response to interferon-alpha therapy:a long term follow-up study in hepatitis C-infected patients with beta thalassemia major. Am J Gastroenterol 2002; 97(4): 982-987.
45. Hofer H, Osterreicher C, Jessner W, Penz M, Steindl-Munda P, Wrba F, et al. Hepatic iron concentration does notpredict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol 2004; 40(6): 1018-1022.
46. Sikorska K, Stalke P, Izycka SE, Romanowski T, Bielawski KP. The role of iron overload and HFE gene mutations in the era of pegylated interferon and ribavirin treatment ofchronic hepatitis C. Med Sci Monit 2010; 16(3): CR137-CR143.
47. Petta S, Camma C, Scazzone C, Tripodo C, Di Marco V, Bono A, et al. Low vitamin D serum level is related to severefibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51(4): 1158-1167.
48. Tran HA, Malcolm Reeves GE, Gibson R, Attia JR. Development of thyroid diseases in the treatment of chronic hepatitis C with alpha-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis. J Gastroenterol Hepatol 2009; 24(7): 1163-1168.
49. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38(3): 645-652.
50. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, MaieronA, Brunner H, et al. Peginterferon alfa-2a and ribavirinfor 24 weeks in hepatitis C type 1 and 4 patients withrapid virological response. Gastroenterology 2008; 135(2): 451-458.
51. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype1-infected slow responders. Hepatology 2007;46(6): 1688-1694.
52. Hadziyannis SJ, Sette HJ, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirincombination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Inter Med 2004; 140(5): 346-355.
53. Dalgard O, Mangia A. Short treatment to patients with genotype 2 or 3. Hepatology 2008; 48(2): 694.
54. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 2008; 47(1): 43-50.
55. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated interferon-alpha-2a plus ribavirin for treatmentnaive Asian patients with hepatitis C virus genotype 1 infection: a multicenter randomized controlled trial. ClinInfect Dis 2008; 47(10): 1260-1269.